GlassScriptPhysician profile
Algernon William Prioleau
NPI 1518462654
$2,426.77
in general payments reported to CMS, 2019-2025
22 companies · $886 in 2025
The $886 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $690 · 2024: $711 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $732.24 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $474.98 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $255.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.27 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $104.76 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.46 | 2023-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $83.74 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Shield Therapeutics INC | $69.63 | 2024-2025 | |
| Axsome Therapeutics, INC. | $64.84 | 2024-2025 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $58.94 | 2025 | |
| Dexcom, INC. | $54.66 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.72 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $34.11 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $33.08 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $26.80 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeza LLC | $24.69 | 2023 | |
| Lundbeck LLC | $24.02 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $17.09 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $16.08 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.96 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $15.82 | 2025 | Zoryve |
| Vericel Corporation | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Algernon Prioleau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.